Isofol has successfully completed the ISO-MTX-003 study in which Modufolin® is evaluated as rescue therapy
Isofol Medical AB announced today that the study ISO-MTX-003 evaluating Modufolin® as rescue therapy (after two cycles of HDMTX treatment) […]
News
Isofol’s largest shareholder and co-founder acquires shares in the company
Isofol Medical AB (publ) announces today that its largest shareholder and co-founder, Bengt Gustavsson, now acquired circa 16 000 shares
Isofol’s Chairman of the Board acquires shares in the company
Isofol Medical AB (publ) announces that its Chairman of the Board, Jan-Eric Österlund, now acquired 15,000 shares in Isofol to
Isofol Medical announces the outcome of the Offering – trading on Nasdaq First North Premier commences today
Isofol Medical AB (publ), a clinical stage pharmaceutical company, hereby announces that the offering of newly issued shares in the
Invitation: Isofol will present it’s contemplated IPO in Stockholm on March 29
In connection with the contemplated IPO of Isofol Medical on Nasdaq First North Premier, we are pleased to invite you
Invitation: Isofol will present it’s contemplated IPO in Göteborg on March 22
In connection with the contemplated IPO of Isofol Medical on Nasdaq First North Premier, we are pleased to invite you
Listing of Isofol Medical on Nasdaq First North Premier and publication of prospectus
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA,
Isofol announces its intention to list on Nasdaq First North Premier
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA,
ISOFOL FILES IMPORTANT NEW US PATENT APPLICATION
Isofol Medical AB (publ) today announces that a new patent application was filed, on February 14, 2017, to the US
FDA CLEARS ISOFOL’S IND APPLICATION TO START CLINICAL PROGRAM WITHIN COLORECTAL CANCER WITH MODUFOLIN®
Isofol Medical AB announces that the US Food and Drug Administration (FDA) has cleared Isofol’s investigational new drug (IND) application